Opportunities for Innovation in Smoking Cessation Therapies: A Perspective From the National Institutes of Health and U.S. Food and Drug Administration

Ann Intern Med. 2024 Oct 15. doi: 10.7326/ANNALS-24-02318. Online ahead of print.

Authors

Haider J Warraich¹, Brian A King¹, Wilson M Compton², Evan S Herrmann², Mary Thanh Hai¹, Robert M Califf¹, Monica M Bertagnolli²

Affiliations

¹ U.S. Food and Drug Administration, Silver Spring, Maryland (H.J.W., B.A.K., M.T.H., R.M.C.).
² National Institutes of Health, Bethesda, Maryland (W.M.C., E.S.H., M.M.B.).

PMID: 39401434
DOI: 10.7326/ANNALS-24-02318

No abstract available

Publication types

Editorial